No Cover Image

Journal article 145 views 25 downloads

Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study

Sharmistha Roy Chowdhury, Fethi Sadouki, Edward Collins, Frederick Keen, Ridhi Bhagi, Yuan S. J. Lim, Silviu L. Cozma, Steve Bain Orcid Logo

Diabetes Therapy, Volume: 15, Issue: 4, Pages: 869 - 881

Swansea University Author: Steve Bain Orcid Logo

  • 65730.VoR.pdf

    PDF | Version of Record

    © The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

    Download (803.04KB)

Check full text

DOI (Published version): 10.1007/s13300-024-01551-4

Abstract

IntroductionSemaglutide, the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) available in subcutaneous and oral formulation for treatment of type 2 diabetes (T2D), has demonstrated clinically significant improvements in glycaemic control and weight in clinical trials. This study aimed to ga...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa65730
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2024-03-04T07:55:06Z
last_indexed 2024-03-04T07:55:06Z
id cronfa65730
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>65730</id><entry>2024-03-04</entry><title>Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-03-04</date><deptcode>BMS</deptcode><abstract>IntroductionSemaglutide, the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) available in subcutaneous and oral formulation for treatment of type 2 diabetes (T2D), has demonstrated clinically significant improvements in glycaemic control and weight in clinical trials. This study aimed to gain insights into the use of both formulations and evaluate their clinical effectiveness in a secondary care clinic in Wales.MethodsThis was a retrospective observational analysis of adults with T2D initiated on oral or subcutaneous semaglutide. Changes from baseline in glycated haemoglobin (HbA1c), weight and other metabolic parameters were evaluated.ResultsAt baseline, participants (n = 103) had a mean age of 57.3 years, mean HbA1c of 79.1 mmol/mol (9.38%), mean weight of 111.8 kg and body mass index (BMI) of 39.6 kg/m2 (no statistically significant differences between oral and subcutaneous groups). At 6-month follow-up, statistically significant improvements in HbA1c (− 19.3 mmol/mol [− 1.77%] and − 20.8 mmol/mol [− 1.90%]), body weight (− 9.0 kg and − 7.2 kg), and BMI (− 3.3 kg/m2 and − 2.5 kg/m2) were observed for oral and subcutaneous semaglutide, respectively. No statistically significant differences between the formulations were observed, and safety profiles were comparable.ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>15</volume><journalNumber>4</journalNumber><paginationStart>869</paginationStart><paginationEnd>881</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>GLP-1 RA; Primary care; Realworld evidence; Secondary care; Semaglutide; Type 2 diabetes</keywords><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-04-01</publishedDate><doi>10.1007/s13300-024-01551-4</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Medical writing and data analysis support and the journal’s rapid service fee was paid for by Novo Nordisk.</funders><projectreference/><lastEdited>2024-04-25T21:40:12.3086518</lastEdited><Created>2024-03-04T07:53:31.7650982</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Sharmistha Roy</firstname><surname>Chowdhury</surname><order>1</order></author><author><firstname>Fethi</firstname><surname>Sadouki</surname><order>2</order></author><author><firstname>Edward</firstname><surname>Collins</surname><order>3</order></author><author><firstname>Frederick</firstname><surname>Keen</surname><order>4</order></author><author><firstname>Ridhi</firstname><surname>Bhagi</surname><order>5</order></author><author><firstname>Yuan S. J.</firstname><surname>Lim</surname><order>6</order></author><author><firstname>Silviu L.</firstname><surname>Cozma</surname><order>7</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>8</order></author></authors><documents><document><filename>65730__30162__462271c284934ee2b93b80a1b11d49c7.pdf</filename><originalFilename>65730.VoR.pdf</originalFilename><uploaded>2024-04-25T21:38:23.0532403</uploaded><type>Output</type><contentLength>822313</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 65730 2024-03-04 Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2024-03-04 BMS IntroductionSemaglutide, the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) available in subcutaneous and oral formulation for treatment of type 2 diabetes (T2D), has demonstrated clinically significant improvements in glycaemic control and weight in clinical trials. This study aimed to gain insights into the use of both formulations and evaluate their clinical effectiveness in a secondary care clinic in Wales.MethodsThis was a retrospective observational analysis of adults with T2D initiated on oral or subcutaneous semaglutide. Changes from baseline in glycated haemoglobin (HbA1c), weight and other metabolic parameters were evaluated.ResultsAt baseline, participants (n = 103) had a mean age of 57.3 years, mean HbA1c of 79.1 mmol/mol (9.38%), mean weight of 111.8 kg and body mass index (BMI) of 39.6 kg/m2 (no statistically significant differences between oral and subcutaneous groups). At 6-month follow-up, statistically significant improvements in HbA1c (− 19.3 mmol/mol [− 1.77%] and − 20.8 mmol/mol [− 1.90%]), body weight (− 9.0 kg and − 7.2 kg), and BMI (− 3.3 kg/m2 and − 2.5 kg/m2) were observed for oral and subcutaneous semaglutide, respectively. No statistically significant differences between the formulations were observed, and safety profiles were comparable.ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D. Journal Article Diabetes Therapy 15 4 869 881 Springer Science and Business Media LLC 1869-6953 1869-6961 GLP-1 RA; Primary care; Realworld evidence; Secondary care; Semaglutide; Type 2 diabetes 1 4 2024 2024-04-01 10.1007/s13300-024-01551-4 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Medical writing and data analysis support and the journal’s rapid service fee was paid for by Novo Nordisk. 2024-04-25T21:40:12.3086518 2024-03-04T07:53:31.7650982 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Sharmistha Roy Chowdhury 1 Fethi Sadouki 2 Edward Collins 3 Frederick Keen 4 Ridhi Bhagi 5 Yuan S. J. Lim 6 Silviu L. Cozma 7 Steve Bain 0000-0001-8519-4964 8 65730__30162__462271c284934ee2b93b80a1b11d49c7.pdf 65730.VoR.pdf 2024-04-25T21:38:23.0532403 Output 822313 application/pdf Version of Record true © The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. true eng http://creativecommons.org/licenses/by-nc/4.0/
title Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
spellingShingle Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
Steve Bain
title_short Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
title_full Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
title_fullStr Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
title_full_unstemmed Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
title_sort Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Sharmistha Roy Chowdhury
Fethi Sadouki
Edward Collins
Frederick Keen
Ridhi Bhagi
Yuan S. J. Lim
Silviu L. Cozma
Steve Bain
format Journal article
container_title Diabetes Therapy
container_volume 15
container_issue 4
container_start_page 869
publishDate 2024
institution Swansea University
issn 1869-6953
1869-6961
doi_str_mv 10.1007/s13300-024-01551-4
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description IntroductionSemaglutide, the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) available in subcutaneous and oral formulation for treatment of type 2 diabetes (T2D), has demonstrated clinically significant improvements in glycaemic control and weight in clinical trials. This study aimed to gain insights into the use of both formulations and evaluate their clinical effectiveness in a secondary care clinic in Wales.MethodsThis was a retrospective observational analysis of adults with T2D initiated on oral or subcutaneous semaglutide. Changes from baseline in glycated haemoglobin (HbA1c), weight and other metabolic parameters were evaluated.ResultsAt baseline, participants (n = 103) had a mean age of 57.3 years, mean HbA1c of 79.1 mmol/mol (9.38%), mean weight of 111.8 kg and body mass index (BMI) of 39.6 kg/m2 (no statistically significant differences between oral and subcutaneous groups). At 6-month follow-up, statistically significant improvements in HbA1c (− 19.3 mmol/mol [− 1.77%] and − 20.8 mmol/mol [− 1.90%]), body weight (− 9.0 kg and − 7.2 kg), and BMI (− 3.3 kg/m2 and − 2.5 kg/m2) were observed for oral and subcutaneous semaglutide, respectively. No statistically significant differences between the formulations were observed, and safety profiles were comparable.ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D.
published_date 2024-04-01T21:40:12Z
_version_ 1797340647077707776
score 11.014358

Similar Items